Literature DB >> 23462326

Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues.

Beatrice Mohelnikova-Duchonova1, Veronika Brynychova, Martin Oliverius, Eva Honsova, Zdenek Kala, Katarina Muckova, Pavel Soucek.   

Abstract

OBJECTIVES: The aim of this study was to evaluate transcript levels of all 49 human ATP-binding cassette transporters (ABCs) in one of the most drug-resistant cancers, namely, the pancreatic ductal adenocarcinoma (PDAC). Association of ABCs levels with clinical-pathologic characteristics and KRAS mutation status was followed as well.
METHODS: Tumors and adjacent nonneoplastic tissues were obtained from 32 histologically verified PDAC patients. The transcript profile of ABCs was assessed using quantitative real-time polymerase chain reaction with a relative standard curve. KRAS mutations in exon 2 were assessed by high-resolution melting analysis and sequencing.
RESULTS: Most ABCs were deregulated in PDAC and 10 ABCs were associated with clinical-pathologic characteristics. KRAS mutations did not change the global expression profile of ABCs.
CONCLUSIONS: The expression of ABC transporters was significantly deregulated in PDAC tumors when compared to nonmalignant tissues. The observed up-regulation of ABCB4, ABCB11, ABCC1, ABCC3, ABCC5, ABCC10, and ABCG2 in tumors may contribute to the generally poor treatment response of PDAC. The up-regulation of ABCA1, ABCA7, and ABCG1 implicates a serious impairment of cellular cholesterol homeostasis in PDAC. On the other hand, the observed down-regulation of ABCA3, ABCC6, ABCC7, and ABCC8 suggests a possible role of stem cells in the development and progression of PDAC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462326     DOI: 10.1097/MPA.0b013e318279b861

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  38 in total

1.  The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.

Authors:  Yuan Yuan; Zhulin Yang; Xiongying Miao; Daiqiang Li; Ziru Liu; Qiong Zou
Journal:  Tumour Biol       Date:  2015-07-16

2.  Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.

Authors:  Rolando A R Villacis; Tatiane R Basso; Luisa M Canto; Maísa Pinheiro; Karina M Santiago; Juliana Giacomazzi; Cláudia A A de Paula; Dirce M Carraro; Patrícia Ashton-Prolla; Maria I Achatz; Silvia R Rogatto
Journal:  J Mol Med (Berl)       Date:  2017-01-16       Impact factor: 4.599

Review 3.  Resistin: An inflammatory cytokine with multi-faceted roles in cancer.

Authors:  Sarabjeet Kour Sudan; Sachin Kumar Deshmukh; Teja Poosarla; Nicolette Paolaungthong Holliday; Donna Lynn Dyess; Ajay Pratap Singh; Seema Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-08-19       Impact factor: 10.680

4.  SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma.

Authors:  Viktor Hlavac; Radka Vaclavikova; Veronika Brynychova; Pavel Dvorak; Katerina Elsnerova; Renata Kozevnikovova; Karel Raus; Katerina Kopeckova; Sona Mestakova; David Vrana; Jiri Gatek; Pavel Soucek
Journal:  Mol Diagn Ther       Date:  2021-01-02       Impact factor: 4.074

Review 5.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

6.  KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.

Authors:  M Oliverius; D Flasarova; B Mohelnikova-Duchonova; M Ehrlichova; V Hlavac; M Kocik; O Strouhal; P Dvorak; I Ojima; P Soucek
Journal:  Mutagenesis       Date:  2019-12-19       Impact factor: 3.000

7.  Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216.

Authors:  B Mohelnikova-Duchonova; M Kocik; B Duchonova; V Brynychova; M Oliverius; J Hlavsa; E Honsova; J Mazanec; Z Kala; I Ojima; D J Hughes; J E Doherty; H A Murray; M A Crockard; R Lemstrova; P Soucek
Journal:  Pharmacogenomics J       Date:  2016-08-30       Impact factor: 3.550

Review 8.  Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.

Authors:  Christopher Gromisch; Motaz Qadan; Mariana Albuquerque Machado; Kebin Liu; Yolonda Colson; Mark W Grinstaff
Journal:  Cancer Res       Date:  2020-03-27       Impact factor: 12.701

9.  The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.

Authors:  Nicolas Skrypek; Romain Vasseur; Audrey Vincent; Bélinda Duchêne; Isabelle Van Seuningen; Nicolas Jonckheere
Journal:  Oncotarget       Date:  2015-05-10

10.  Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes.

Authors:  Anke Van den Broeck; Hugo Vankelecom; Wouter Van Delm; Lies Gremeaux; Jasper Wouters; Joke Allemeersch; Olivier Govaere; Tania Roskams; Baki Topal
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.